The Evidence Based Rheumatology Podcast

E45: TNF or TCZ or ABA or RTX: Real World Data for RA

This week I tackle an interesting cohort study that Jack Cush (@RheumNow) mentioned in his podcast.  It's a nice opportunity to discuss bDMARDs in the "real world" (AKA Sweden).  Follow me @ebrheum and let me know what you think of the episode! 

E44: SELECT-COMPARE Upadacitinib (JAKi) for Rheumatoid Arthritis

Finally got around to tackling the JAKi this week.  I decided to focus on SELECT-COMPARE, which pitted upadacitinib (selective JAK1 inhibitor) against adalimumab and placebo.  I briefly discuss other JAKs and my thoughts on the future of this area. Get the paper and others at ebrheum.com and follow me @ebrheum! 

E43: Tofacitinib for MDA5 Amyopathic Dermatomyositis ILD

Back this week to discuss an interesting paper in the NEJM.  Lots of interesting issues, most notably historical controls and their limitations.  Find all my work at ebrheum.com!